Aadi bioscience to present multiple posters on nab-sirolimus at the 2023 american association for cancer research (aacr) annual meeting

Los angeles , april 14, 2023 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mtor pathway genes, today announced the presentation of three posters at the 2023 american association for cancer research annual meeting (aacr), taking place april 14-19, 2023, in orlando, fl.
AADI Ratings Summary
AADI Quant Ranking